Heavy menstrual bleeding (HMB) is a common and burdensome symptom in women with von Willebrand disease (VWD). Although VWD and HMB have been studied, the prevalence and impact of HMB across different age...
Lire la suite

Von Willebrand disease (VWD) is the most common inherited bleeding disorder, affecting up to 1% of the population. Over the past two decades, there has been significant progress in understanding its pathophysiology,...
Lire la suite

Although clinical experience of a triple-secured, plasma-derived, von Willebrand factor (pdVWF), almost devoid of Factor VIII (FVIII) in adults with von Willebrand disease (VWD), is widely reported, its...
Lire la suite

In surgical settings, managing von Willebrand disease (VWD) often requires von Willebrand Factor (VWF) concentrate administration and close monitoring of FVIII and VWF to balance bleeding control with the risk of excessive factor elevation. This management is further complicated by VWD-related variability and the pharmacokinetic (PK) impact of VWF products, containing or not exogenous FVIII. We hypothesized that building a PK model based on high-purity...
Lire la suite